Cargando…
Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration
Bevacizumab (Avastin(®)) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated tha...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Open
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394187/ https://www.ncbi.nlm.nih.gov/pubmed/22798970 http://dx.doi.org/10.2174/1874364101206010054 |